---
figid: PMC7014257__ijms-21-00565-g002
figlink: pmc/articles/PMC7014257/figure/ijms-21-00565-f002/
number: F2
caption: 'Strategies to overcome anti-angiogenic therapy resistance. Resistance to
  anti-angiogenic drugs in lung cancer (right) could be delayed by (1) the natural
  compound EGCG, which exerts its antiangiogenic effect by suppressing the expression
  of VEGF-A and HIF-1α and increasing the expression of angiogenesis inhibitor endostatin
  in cancer cells; (2) the combination of bevacizumab with immunotherapy, such as
  the adoptive transfer of cytokine-induced killer cells; (3) the inhibition of angiogenic
  VEGFR co-receptors NP1 and NP2 through histone deacetylase inhibitor SAHA; (4) the
  inhibition of the translation of VEGF-A mRNA in lung cancer cell and VEGFR-2 and
  VEGFR-3 mRNA in endothelial cells with microRNA-128; and (5) the use of the multi
  tyrosine kinase inhibitor nintedanib, which targets VEGFR1, VEGFR2, VEGFR3, PDGF,
  and FGFR. On the other hand, for breast cancer (right), the strategies to overcome
  anti-angiogenic therapy resistance include (1) the use of green tea extract EGCG
  to decrease the expression of VEGF transcription modulator PKC; (2) the combination
  of antiangiogenic antibody CVX-241 with the anti-programmed death-ligand 1 (anti-PD-L1)
  antibody; (3) the combination of bevacizumab with camptothecin which inhibits HIF-1α;
  (4) the use of epigenetic modulator SAHA to suppress VEGF-C expression; (5) the
  blocking of chemokine CCL18, which is secreted by TAM, and CCL18 receptor on endothelial
  cells; and (6) the inhibition of the signal transduction pathway of VEGFR2 in endothelial
  cells through the down-regulation of signaling regulators (Ephrin type-B receptor
  2) EphB2 and Disabled homolog 2 (Dab2). Abbreviations: EGCG, epigallocatechin-3-O-gallate;
  VEGF, vascular endothelial growth factor; HIF-1α, hypoxia inducible factor-1α; SAHA,
  suberanilohydroxamic acid; HDAC, histone deacetylase; NP1, neuropilin1; NP2, neuropilin2;
  miR, microRNA; PDGF, platelet-derived growth factor receptor; FGFR, fibroblast growth
  factor receptor; Ang2, angiopoietin 2; PD-L1, programmed death-ligand 1; PLC-γ,
  phospholipase C-γ; PKC, protein kinase C; and TAM, tumor-associated macrophage.'
pmcid: PMC7014257
papertitle: Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding
  the Anti-Angiogenesis Resistance Mechanisms.
reftext: Wafaa S. Ramadan, et al. Int J Mol Sci. 2020 Jan;21(2):565.
pmc_ranked_result_index: '77958'
pathway_score: 0.938973
filename: ijms-21-00565-g002.jpg
figtitle: Strategies to overcome anti-angiogenic therapy resistance
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7014257__ijms-21-00565-g002.html
  '@type': Dataset
  description: 'Strategies to overcome anti-angiogenic therapy resistance. Resistance
    to anti-angiogenic drugs in lung cancer (right) could be delayed by (1) the natural
    compound EGCG, which exerts its antiangiogenic effect by suppressing the expression
    of VEGF-A and HIF-1α and increasing the expression of angiogenesis inhibitor endostatin
    in cancer cells; (2) the combination of bevacizumab with immunotherapy, such as
    the adoptive transfer of cytokine-induced killer cells; (3) the inhibition of
    angiogenic VEGFR co-receptors NP1 and NP2 through histone deacetylase inhibitor
    SAHA; (4) the inhibition of the translation of VEGF-A mRNA in lung cancer cell
    and VEGFR-2 and VEGFR-3 mRNA in endothelial cells with microRNA-128; and (5) the
    use of the multi tyrosine kinase inhibitor nintedanib, which targets VEGFR1, VEGFR2,
    VEGFR3, PDGF, and FGFR. On the other hand, for breast cancer (right), the strategies
    to overcome anti-angiogenic therapy resistance include (1) the use of green tea
    extract EGCG to decrease the expression of VEGF transcription modulator PKC; (2)
    the combination of antiangiogenic antibody CVX-241 with the anti-programmed death-ligand
    1 (anti-PD-L1) antibody; (3) the combination of bevacizumab with camptothecin
    which inhibits HIF-1α; (4) the use of epigenetic modulator SAHA to suppress VEGF-C
    expression; (5) the blocking of chemokine CCL18, which is secreted by TAM, and
    CCL18 receptor on endothelial cells; and (6) the inhibition of the signal transduction
    pathway of VEGFR2 in endothelial cells through the down-regulation of signaling
    regulators (Ephrin type-B receptor 2) EphB2 and Disabled homolog 2 (Dab2). Abbreviations:
    EGCG, epigallocatechin-3-O-gallate; VEGF, vascular endothelial growth factor;
    HIF-1α, hypoxia inducible factor-1α; SAHA, suberanilohydroxamic acid; HDAC, histone
    deacetylase; NP1, neuropilin1; NP2, neuropilin2; miR, microRNA; PDGF, platelet-derived
    growth factor receptor; FGFR, fibroblast growth factor receptor; Ang2, angiopoietin
    2; PD-L1, programmed death-ligand 1; PLC-γ, phospholipase C-γ; PKC, protein kinase
    C; and TAM, tumor-associated macrophage.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - KDR
  - TNFRSF10B
  - CD274
  - VEGFD
  - VEGFB
  - PGF
  - VEGFC
  - HIF1A
  - PRKCA
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCQ
  - PRKCB
  - PRKCD
  - PRKCI
  - PRKCZ
  - PRKD3
  - NPL
  - HDAC2
  - HDAC3
  - HDAC9
  - HDAC4
  - HDAC6
  - SIRT2
  - SIRT4
  - HDAC8
  - HDAC11
  - HDAC1
  - HDAC5
  - SIRT5
  - SIRT3
  - SIRT1
  - SIRT7
  - SIRT6
  - HDAC7
  - HDAC10
  - FLT4
  - CCL18
  - DAB2
  - EPHA2
  - EGCG
  - Camptothecin
  - Endostatin
  - SAHA
  - TAM
  - cancer cell Breast cancer
genes:
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGFR-2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: killer
  symbol: KILLER
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF10B
  entrez: '8795'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: HIF-1a
  symbol: HIF1A
  source: hgnc_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: VEGF-C
  symbol: VEGFC
  source: hgnc_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: NP1
  symbol: NPL
  source: hgnc_symbol
  hgnc_symbol: NPL
  entrez: '80896'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC2
  entrez: '3066'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC3
  entrez: '8841'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC9
  entrez: '9734'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC4
  entrez: '9759'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT2
  entrez: '22933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT4
  entrez: '23409'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC8
  entrez: '55869'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC11
  entrez: '79885'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC1
  entrez: '3065'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC5
  entrez: '10014'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT5
  entrez: '23408'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT3
  entrez: '23410'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT1
  entrez: '23411'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT7
  entrez: '51547'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT6
  entrez: '51548'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC7
  entrez: '51564'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC10
  entrez: '83933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC2
  entrez: '3066'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC3
  entrez: '8841'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC9
  entrez: '9734'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC4
  entrez: '9759'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT2
  entrez: '22933'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT4
  entrez: '23409'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC8
  entrez: '55869'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC11
  entrez: '79885'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC1
  entrez: '3065'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC5
  entrez: '10014'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT5
  entrez: '23408'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT3
  entrez: '23410'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT1
  entrez: '23411'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT7
  entrez: '51547'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: SIRT6
  entrez: '51548'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC7
  entrez: '51564'
- word: HDAC
  symbol: HDAC
  source: bioentities_symbol
  hgnc_symbol: HDAC10
  entrez: '83933'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGFR3
  symbol: VEGFR3
  source: hgnc_alias_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: CCL18
  symbol: CCL18
  source: hgnc_symbol
  hgnc_symbol: CCL18
  entrez: '6362'
- word: VEGFR3
  symbol: VEGFR3
  source: hgnc_alias_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: Dab2
  symbol: DAB2
  source: hgnc_symbol
  hgnc_symbol: DAB2
  entrez: '1601'
- word: VEGFR-2,
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: Dab2
  symbol: DAB2
  source: hgnc_symbol
  hgnc_symbol: DAB2
  entrez: '1601'
- word: Epha2
  symbol: EPHA2
  source: hgnc_symbol
  hgnc_symbol: EPHA2
  entrez: '1969'
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGFR-2/3
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
chemicals:
- word: EGCG
  source: MESH
  identifier: C045651
- word: Camptothecin
  source: MESH
  identifier: D002166
- word: Endostatin
  source: MESH
  identifier: D043169
- word: SAHA
  source: MESH
  identifier: C111237
- word: TAM
  source: MESH
  identifier: C419191
diseases:
- word: cancer cell Breast cancer
  source: MESH
  identifier: D001943
figid_alias: PMC7014257__F2
redirect_from: /figures/PMC7014257__F2
figtype: Figure
---
